LAMP3 and neoplasm: Lysosome associated membrane protein-3 (LAMP3) represents another tumor promoting protein for which the greatest downregulation was observed during dual therapy (35.0%) compared to DPCP monotherapy (16.5%) or pembrolizumab monotherapy (2.1%).